Novel Developments in Stem Cell Mobilization Focus on CXCR4 /
Recently, the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development...
Đã lưu trong:
| Tác giả của công ty: | |
|---|---|
| Tác giả khác: | , , |
| Định dạng: | Điện tử eBook |
| Ngôn ngữ: | English |
| Được phát hành: |
New York, NY :
Springer New York : Imprint: Springer,
2012.
|
| Phiên bản: | 1st ed. 2012. |
| Những chủ đề: | |
| Truy cập trực tuyến: | https://doi.org/10.1007/978-1-4614-1960-0 |
| Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| Tóm tắt: | Recently, the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development of effective antagonists. One antagonist, plerixafor, is now clinically approved for stem cell mobilization of lymphoma and myeloma patients. This progress allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoietic cells, i.e. leukemia cells. In preclinical studies, a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. CXCR4 antagonists are an exciting new class of compounds which are also used for the mobilization of angiogenic cells or for the treatment of solid tumors. This book provides concise reviews of novel developments, as well as possible future developments on CXCR4. . |
|---|---|
| Mô tả vật lý: | XIV, 498 p. online resource. |
| số ISBN: | 9781461419600 |